The purpose of this study is to evaluate the pharmacokinetics, safety, tolerability and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants with at least 1 triple combination responsive (TCR) mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Cystic Fibrosis
The purpose of this study is to evaluate the pharmacokinetics, safety, tolerability and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants with at least 1 triple combination responsive (TCR) mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age
-
Children's Hospital of Orange County, Orange, California, United States, 92868
Stanford University, Palo Alto, California, United States, 94304
Children's Hospital of Colorado, Aurora, Colorado, United States, 80045
The Emory Clinic / Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States, 30322
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States, 60611
Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, United States, 46202
Boston Children's Hospital, Boston, Massachusetts, United States, 02115
Children's Respiratory and Critical Care Specialists, P.A., Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States, 55404
The Children's Mercy Hospital, Kansas City, Missouri, United States, 64108
Washington University School of Medicine / St. Louis Children's Hospital, Saint Louis, Missouri, United States, 63110
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
1 Year to 11 Years
ALL
No
Vertex Pharmaceuticals Incorporated,
2030-06